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Summary		
Understanding	 the	 circuits	 that	 promote	 an	 efficient	 resolution	 of	 inflammation	 is	 crucial	 to	
deciphering	 the	molecular	 and	 cellular	 processes	 required	 to	 promote	 tissue	 repair.	Macrophages	
play	 a	 central	 role	 in	 the	 regulation	 of	 inflammation,	 resolution	 and	 repair/regeneration.	 Using	 a	
model	 of	 skeletal	 muscle	 injury	 and	 repair,	 herein	 we	 identified	 Annexin	 A1	 (AnxA1)	 as	 the	
extracellular	trigger	of	macrophage	skewing	towards	a	pro-reparative	phenotype.	Brought	 into	the	
injured	tissue	initially	by	migrated	neutrophils,	and	then	over-expressed	in	infiltrating	macrophages,	
AnxA1	 activated	 FPR2/ALX	 receptors	 and	 the	 downstream	 AMPK	 signalling	 cascade	 leading	 to	
macrophage	 skewing,	dampening	of	 inflammation	and	 regeneration	of	muscle	 fibres.	Mice	 lacking	
AnxA1	 in	 all	 cells	 or	 in	 myeloid	 cells	 only	 displayed	 a	 defect	 in	 this	 reparative	 process.	 In	 vitro	
experiments	 recapitulated	 these	properties,	with	AMPK	null	macrophages	 lacking	AnxA1-mediated	
polarisation.	Collectively,	these	data	identified	the	AnxA1/FPR2/AMPK	axis	as	an	important	pathway	
in	skeletal	muscle	injury	regeneration.	
	
Keywords:	 macrophage	 switch,	 resolution	 of	 inflammation,	 tissue	 repair,	 skeletal	 muscle	
homeostasis	
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Introduction		
An	efficient	inflammatory	response	is	a	necessary	component	of	the	reaction	to	injury	or	infection,	
but	it	is	equally	critical	for	this	inflammatory	response	to	be	terminated	in	a	timely	and	appropriate	
manner,	 enabling	 the	 restoration	 of	 tissue	 homeostasis	 (1,	 2).	 Indeed,	 chronic	 inflammation	 that	
results	 from	 failure	 of	 resolution	 represents	 a	 major	 contributing	 factor	 to	 a	 multitude	 of	
pathologies,	from	arthritis	to	sepsis	to	dementia	(3,	4)	
	
An	 inflammatory	 reaction	 consists	 of	 the	 co-ordinated	 activity	 of	 numerous	 cells	 and	 soluble	
mediators,	but	a	central	role	is	played	by	the	macrophage.	These	cells,	whether	resident	in	the	tissue	
or	recruited	from	circulating	monocyte	populations,	are	amongst	the	first	responders	to	pathogen-	
or	 damage-associated	 molecular	 patterns,	 initiating	 endothelial	 activation	 and	 neutrophil	
recruitment	 (5).	 Beyond	 their	 roles	 as	 sentinels,	 macrophages	 are	 important	 drivers	 of	 the	
progression	 of	 an	 inflammatory	 response,	 acting	 to	 clear	 pathogens,	 effete	 cells	 and	 debris	 by	
phagocytosis	 (6),	 serving	 as	 antigen	 presenting	 cells	 to	 recruit	 the	 adaptive	 arm	 of	 the	 immune	
response	(7),	and	ultimately	enabling	processes	of	tissue	repair	and	resolution	(8,	9).	That	one	cell	
type	is	able	to	achieve	this	diverse	array	of	functions	is	due	in	large	part	to	its	remarkable	degree	of	
phenotypic	 plasticity,	 and	 as	 such	 macrophages	 may	 exist	 in	 a	 wide	 variety	 of	 forms	 along	 a	
spectrum	running	from	a	largely	pro-inflammatory	state,	often	indicated	as	M1,	to	a	primarily	non-
phlogistic	and	pro-resolving	phenotype,	termed	M2	(10).		
	
A	 number	 of	 factors	 promoting	 this	 phenotypic	 transformation	 have	 been	 studied	 including	
exposure	 to	 anti-inflammatory	 cytokines	 such	 as	 interleukin	 (IL)-10	 and	 IL-4,	 and	 the	 phagocytic	
removal	of	cell	debris,	although	a	complete	description	of	the	underlying	mechanisms	is	lacking	(11).	
We	and	others	have	identified	a	key	role	for	the	intracellular	signalling	pathway	governed	by	AMP-
activated	 protein	 kinase	 (AMPK)	 (12–14).	 Activation	 of	 this	 pathway	 is	 required	 for	 efficient	
conversion	 of	 pro-	 to	 anti-inflammatory-type	 macrophages,	 and	 inhibition	 of	 such	 a	 response	
significantly	 attenuated	 recovery	 in	 a	 model	 of	 inflammatory	 skeletal	 muscle	 injury	 (13).	 Whilst	
AMPK	is	undoubtedly	important	in	the	phenotypic	conversion	of	macrophages	during	the	course	of	
an	 inflammatory	 reaction,	 the	 nature	 of	 the	 extracellular	 trigger(s)	 for	 its	 stimulation	 remains	
unclear.		
	
The	 protein	 annexin	 A1	 (ANXA1)	 (15,	 16)	 is	 a	major	 driver	 of	 inflammatory	 resolution,	 promoting	
neutrophil	apoptosis	(17),	non-phlogistic	monocyte	recruitment	(18)	and	macrophage	efferocytosis	
(19,	20).	Moreover,	we	and	others	have	recently	provided	evidence	showing	ANXA1	to	promote	an	
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anti-inflammatory	macrophage	phenotype	in	in	vitro	models	of	rheumatoid	arthritis	(21)	and	tumour	
growth	(22),	but	how	this	translates	to	an	in	vivo	situation	is	less	clear.	Against	this	background,	we	
applied	 a	 well-characterised	 model	 of	 skeletal	 muscle	 injury	 (23–25)	 to	 test	 the	 hypothesis	 that	
ANXA1	and	its	receptor	FPR2/ALX	could	be	the	upstream	trigger	of	AMPK	activation,	and	hence	be	a	
major	driver	of	the	pro-	to	anti-inflammatory	macrophage	phenotype	shift,	promoting	inflammatory	
resolution	and	the	restoration	of	skeletal	muscle	tissue	homeostasis.		
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Results		
	
Annexin	A1	and	Fpr2/3	null	mice	show	impaired	recovery	from	skeletal	muscle	injury	
To	investigate	the	role	of	ANXA1	and	its	receptor	FPR2/ALX	(in	humans,	or	the	orthologue	Fpr2/3	in	
mice)	 in	 the	 control	 of	macrophage	 phenotype	we	 first	 utilised	 the	murine	model	 of	 cardiotoxin-
induced	Tibialis	Anterior	(TA)	injury,	a	model	characterised	by	necrotic	tissue	damage	and	extensive	
macrophage	activity	(13,	26).		
	
Whilst	uninjured	TA	muscle	weight	and	myofibre	size	were	comparable	between	wild-type,	AnxA1-/-	
and	Fpr2/3-/-	mice	 (Fig	1A-B,	 Suppl	 Fig	1A-B),	 recovery	of	muscle	mass	 following	administration	of	
cardiotoxin	was	significantly	reduced	in	AnxA1-/-	and	Fpr2/3-/-	mice	than	in	wild-type	animals	(Fig	1B).	
Histological	 analysis	 of	muscles	 28	 days	 post-injury	 revealed	 significantly	 reduced	myofibre	 cross-
sectional	area	(CSA)	and	myonuclei	per	 fibre	(i.e.,	the	result	of	differentiation	and	fusion	of	muscle	
stem	cells)	 in	AnxA1-/-	and	Fpr2/3-/-	animals	 (Fig	1C-E).	These	outcomes	are	suggestive	of	 impaired	
skeletal	muscle	regeneration,	a	notion	confirmed	by	marked	lipid	accumulation	in	AnxA1-/-	mice	(Fig	
1F,	 Suppl	 Fig	 1D).	 Analysis	 of	 immune	 cell	 infiltration	 by	 flow	 cytometry	 revealed	 that	 2	 days	
following	cardiotoxin	administration,	approximately	60%	of	macrophages	expressed	a	pro-resolving,	
anti-inflammatory	phenotype	(CD45+Ly6C/GnegF4/80hi)	in	wild-type	mice,	whilst	AnxA1-/-	and	Fpr2/3-/-	
animals	 showed	 comparable	 levels	 of	 pro-	 (CD45+Ly6C/GhiF4/80low)	 and	 anti-inflammatory	
(CD45+Ly6C/GlowF4/80hi)	cells	(Fig	1G,	Suppl	Fig	1E).	Consequently,	the	resolution	index	(ratio	of	anti-	
to	pro-inflammatory	macrophages)	of	AnxA1-/-	and	Fpr2/3-/-	mice	was	significantly	lower	than	that	of	
wild-type	animals,	 indicative	of	a	prolonged	inflammatory	response	(Fig	1H).	These	results	 indicate	
that	 a	 proportion	 of	 pro-inflammatory	 macrophages	 failed	 to	 convert	 to	 an	 anti-inflammatory	
phenotype	 at	 the	 time	 of	 resolution	 in	 the	 absence	 of	 AnxA1	 or	 Fpr2/3.	 Inactivation	 of	 the	 Fpr1	
receptor,	 another	 member	 of	 the	 Fpr	 family,	 did	 not	 reproduce	 these	 results	 (Suppl	 Fig	 1F-G),	
suggesting	 a	 specific	 role	 of	 the	 AnxA1-Fpr2/3	 pathway	 in	 these	 settings	 of	 cardiotoxin	 induced	
muscle	injury	and	repair.	
	
Macrophages	are	the	major	source	of	AnxA1	in	lesion	recovery	
The	more	pronounced	effects	of	cardiotoxin	in	AnxA1-/-	and	Fpr2/3-/-	mice	indicate	that	this	pathway	
exerts	 important	 regulatory	 functions	 in	 skeletal	muscle	 injury.	We	 then	 characterised	AnxA1	 and	
Fpr2/3	expression	kinetics	during	skeletal	muscle	regeneration.	Monitoring	ANXA1	expression	in	the	
tissue	revealed	that	while	essentially	non-detectable	in	uninjured	tissue,	the	protein	was	transiently	
induced	from	day	1	to	day	4	post-lesioning	with	much	lower	levels	by	day	7	(Fig	2A).	AnxA1	mRNA	
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analysis	on	FACS-sorted	cell	populations	(Fig	2B,	Suppl	Fig	3A)	combined	with	immunostaining	(Suppl	
Fig	 3B-D)	 indicated	 that	 this	 mediator	 was	 primarily	 restricted	 to	 immune	 cells	 until	 day	 2	 post-
lesioning.	Whilst	 F4/80+	murine	macrophages	expressed	AnxA1	at	 all	 time-points	examined	 (Suppl	
Fig	 3B-C),	 the	proportion	of	macrophages	 expressing	 its	 primary	 receptor,	 Fpr2/3,	 decreased	over	
time,	from	approximately	95%	at	day	2	to	70%	at	day	7	and	finally	to	5%	two	weeks	post-lesioning,	
even	though	significant	numbers	of	macrophages	were	still	detected	 in	the	tissue	(Suppl	Fig	4B-C).	
Importantly,	expression	of	Fpr2/3	on	muscle	fibres	was	not	apparent	at	any	time-point	examined,	as	
it	was	restricted	to	neutrophils	and	pro-inflammatory	macrophages	(Suppl	Fig	4).		
	
We	next	sought	to	functionally	validate	the	role	of	this	 immune	cell-derived	ANXA1	using	chimeric	
mice	 bearing	wild-type	muscle	 but	 AnxA1-/-	 bone	marrow-derived	 leukocytes.	 Therefore,	 CX3CR1-
GFP	mice,	which	harbour	GFP-expressing	monocytes/macrophages	were	irradiated	and	transplanted	
with	 wild-type	 or	 AnxA1-/-	 derived	 bone	 marrow	 cells,	 prior	 to	 injection	 of	 cardiotoxin	 in	 the	 TA	
muscle	 (Fig	 2C).	Analysis	 of	 bone	marrow	populations	 at	 the	 time	of	 euthanasia	 showed	 that	 less	
than	1%	of	monocytes	(CD115pos	cells)	expressed	GFP,	suggesting	>99%	engraftment	efficiency	with	
either	wild-type	or	AnxA1-/-	bone	marrow	(Suppl	Fig	5B-C).	Weight	recovery	was	similar	after	wild-
type	or	AnxA1-/-	 transplant	 (Suppl	Fig	5A),	but	histological	analysis	of	TA	muscles	28-days	post-CTX	
injury	 revealed	that	animals	 receiving	AnxA1-/-	bone	marrow	cells	displayed	a	significantly	 reduced	
myofibre	CSA	than	animals	receiving	wild-type	bone	marrow	cells	(Fig	2D-E).	Since	more	than	90%	of	
the	macrophages	present	in	the	injured	muscles	originated	from	the	transplanted	marrow	(Suppl	Fig	
5D-E),	 these	 data	 indicate	 that	 the	 defective	 regeneration	 quantified	 in	 AnxA1-/-	 muscle	 is	 a	
consequence	of	an	intrinsic	defect	in	myeloid,	rather	than	stromal,	cells.	
	
Exogenous	ANXA1	can	induce	human	macrophage	phenotype	conversion	in	vitro	
As	our	murine	analyses	indicate	a	potential	role	for	AnxA1	in	the	polarisation	of	macrophages	from	a	
pro-inflammatory	 to	 a	 pro-resolving/reparative	 phenotype,	 we	 investigated	 these	 effects	 in	 vitro	
using	human	PBMC-derived	macrophages.	An	M1-like	macrophage	phenotype	was	induced	by	24	h	
incubation	with	bacterial	lipopolysaccharide	(LPS)	and	γ-interferon	(IFNγ),	prior	to	addition	of	human	
recombinant	 ANXA1	 (hrANXA1).	 Following	 hrANXA1	 treatment,	 analysis	 of	 cell	 surface	 markers	
revealed	 a	 significant	 reduction	 in	 expression	 of	 the	M1	marker	 protein	major	 histocompatibility	
complex	 II	 (MHCII)	 (Fig	3A),	accompanied	by	a	significant	 increase	 in	expression	of	 the	M2	marker	
protein	 CD206	 (Fig	 3B).	 These	 surface	 marker	 changes	 were	 mirrored	 by	 changes	 at	 the	
transcriptional	level,	with	hrANXA1	treatment	inducing	a	reduction	in	mRNA	expression	for	the	pro-
inflammatory	genes	Tnfa	and	Nos2	paired	with	increased	message	of	Il-10	(Fig	3C-E).	No	significant	
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changes	 in	Tgfb1	 expression	were	quantified	 (Fig	3F).	 Together,	 these	 in	 vitro	 data	 support	our	 in	
vivo	 findings,	 providing	 evidence	 that	 ANXA1	 application	 favours	 a	 pro-resolving	 macrophage	
phenotype.		
	
Intriguingly,	 we	 observed	 significant	 FPR2/ALX	 surface	 expression	 both	 in	 unstimulated	 human	
PBMC-derived	macrophages	and	M1-phenotype	cells,	yet	cell	surface	expression	of	the	receptor	was	
lost	 on	 cells	 stimulated	 towards	 an	 M2	 phenotype	 with	 IL-4	 (Suppl	 Fig	 4).	 These	 data	 are	 in	
agreement	 with	 the	 in	 vivo	 observation	 that	 Fpr2/3-/-	 is	 absent	 from	 macrophages	 that	 have	
infiltrated	 the	 injured	muscle	 at	Day	7	 and	beyond,	 that	 is,	when	a	 reparative	 cell	 phenotype	has	
been	 acquired	 (Suppl	 Fig	 2B-C).	 The	 functional	 engagement	 of	 FPR2/ALX	 was	 then	 confirmed	
through	 the	 use	 of	 the	 selective	 antagonist	 WRW4.	 The	 modulatory	 effects	 of	 hrANXA1	 on	 pro-
inflammatory	 PBMC-derived	macrophages	 (i.e.	 reduced	 surface	MHCII	 expression	 and	 augmented	
surface	CD206	expression)	were	lost	in	the	presence	of	WRW4	(Fig.	3G-H).		
	
Together	 these	 experiments	 represent	 a	 clear	 in	 vitro	 counterpart	 to	 the	 effects	 observed	 in	 the	
muscle	 injury	model,	 showing	 the	 key	 role	 of	 ANXA1	 acting	 through	 FPR2/ALX	 to	 drive	 a	 shift	 in	
macrophage	phenotype	towards	a	pro-resolving	and	reparative	polarisation.		
	
Exogenous	ANXA1	treatment	stimulates	AMPK	activation	through	FPR2/ALX	
The	 enzyme	 5'-adenosine	monophosphate-activated	 protein	 kinase,	 AMPK,	 plays	 a	 critical	 role	 in	
macrophage	 phenotype	 skewing	 and	 is	 necessary	 for	 efficient	 regeneration	 after	 skeletal	 muscle	
damage	 (13).	We	queried	whether	 this	 signalling	 pathway	would	 underlie	 the	 effects	 of	 hrANXA1	
upon	human	macrophage	phenotype	and	indeed	muscle	repair	in	vivo.	
	
Exposure	of	human	PBMC-derived	macrophages	to	hrANXA1	activated	a	number	of	components	of	
the	 AMPK	 signalling	 pathway,	 promoting	 phosphorylation	 of	 Ca2+/calmodulin-dependent	 protein	
kinase	II,	AMPKα	itself	and	its	downstream	effector	acetyl-CoA	carboxylase	(Fig	4A-B).	Interestingly,	
phosphorylation	of	these	proteins	in	macrophages	only	occurred	to	an	appreciable	degree	following	
exposure	to	hrANXA1	for	30-60	min	(Fig	4B-D),	in	contrast	to	early	MAP	kinase	signalling	previously	
reported	in	human	monocytes	(18).	That	activation	of	AMPKα	depended	upon	binding	of	hrANXA1	
to	 FPR2/ALX	 was	 confirmed	 through	 analysis	 of	 the	 effects	 of	 the	 antagonist	 WRW4,	 which	
abrogated	hrANXA1-evoked	AMPKα	phosphorylation	in	human	macrophages	(Fig	4E).	The	specificity	
of	 hrANXA1	 action	 through	 its	 human	 receptor	 FPR2/ALX	was	 also	 determined	with	 Fpr2/3-/-	 cells	
lacking	the	orthologue	of	the	human	FPR2/ALX	(27).	Analyses	of	murine	BMDM	from	wild-type	and	
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Fpr2/3-/-	animals	confirmed	the	pivotal	role	of	this	receptor:	whilst	treatment	with	hrANXA1	induced	
phosphorylation	of	AMPKα	in	wild-type	cells,	this	response	was	absent	in	macrophages	from	Fpr2/3-
/-	mice	(Fig	4F).	
	
AMPK	activation	is	required	for	macrophage	phenotype	conversion	induced	by	ANXA1	
We	 investigated	 the	 relationship	 between	 FPR2/ALX-mediated	 AMPK	 activation	 and	 the	 shift	 in	
macrophage	phenotype	 induced	by	hrANXA1	 treatment	 through	analyses	 in	primary	BMDM	taken	
from	wild-type	mice	and	animals	lacking	the	key	catalytic	α1	subunit	of	AMPK	(28).	Whilst	treatment	
of	wild-type	macrophages	with	hrANXA1	(10	nM,	6h)	reduced	the	percentage	of	cells	positive	for	the	
pro-inflammatory	markers	iNOS	and	CCL3,	this	response	was	notably	absent	in	cells	from	AMPKα1-/-	
mice	 (Fig	 5A).	 Correspondingly,	 hrANXA1	 treatment	 augmented	 the	 proportion	 of	 wild	 type	 cells	
expressing	 the	 anti-inflammatory	markers	 TGFβ1	 (notably	 at	 variance	 from	human	macrophages),	
CD163	 and	 CD206,	 but	 this	 did	 not	 occur	 in	 cells	 lacking	 AMPKα1	 (Fig	 5B).	 Together,	 these	 data	
indicate	activation	of	AMPKα1	as	a	key	step	in	the	macrophage	phenotype	shift	induced	by	ANXA1.		
	
To	confirm	these	findings	in	human	cells,	we	employed	an	RNA	interference	approach,	transfecting	
primary	 PBMC-derived	 macrophages	 with	 three	 distinct	 siRNA	 constructs	 targeting	 the	 AMPKα1	
subunit	 (Fig	5C).	 Treatment	of	M1-like	pro-inflammatory	macrophages	 for	6	h	with	10	nM	ANXA1	
reduced	the	expression	of	MHCII	and	augmented	that	of	CD206	in	mock	transfected	cells	and	in	cells	
bearing	a	non-targeting	siRNA	construct;	this	effect	was	absent	in	cells	transfected	with	any	of	three	
different	siRNA	constructs	targeting	human	AMPKα1	(Fig	5D-E,	Suppl	Fig	7A).		
	
Adult	myogenesis	is	ANXA1-AMPK	signalling	dependent	in	vitro	
Together,	data	from	the	experiments	with	human	and	mouse	macrophages	make	a	compelling	case	
that	 macrophage	 phenotype	 shifting	 can	 be	 induced	 through	 an	 ANXA1/FPR2/AMPK	 cascade.	 To	
investigate	whether	this	process	underlies	differences	in	recovery	from	cardiotoxin-induced	muscle	
lesions	 seen	 between	 wild-type	 and	 AnxA1-/-	 and	 Fpr2/3-/-	 mice,	 we	 made	 use	 of	 an	 established	
model	of	in	vitro	muscle	repair	(13,	29).		
	
We	 employed	 an	 in	 vitro	model	 of	 adult	myogenesis	 in	which	 conditioned	medium	 from	 primary	
BMDM	 was	 used	 to	 stimulate	 primary	 murine	 myoblasts	 for	 72h,	 quantifying	 the	 proportion	 of	
multinucleated	myotubes	 (Fig	5F).	As	such	 this	 in	vitro	 setting	 recapitulates	 the	processes	of	adult	
myogenesis	 (activation,	 differentiation,	 migration	 and	 fusion	 of	 muscle	 cells)	 that	 occur	 during	
skeletal	 muscle	 regeneration	 (13,	 29).	 Conditioned	 medium	 from	 ANXA1-treated	 wild-type	
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macrophages	augmented	the	myotube	fusion	index	(Fig	5G-I).	This	response	was	not	observed	when	
myotubes	were	treated	with	conditioned	medium	from	ANXA1-treated	AMPKα1-/-	macrophages	(Fig	
5G-I).	 Direct	 addition	 of	 ANXA1	 (10	 nM)	 to	myoblast	 cultures	 did	 not	 regulate	 the	 extent	 of	 cell	
fusion	(Suppl	Fig	7B).	
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Discussion	
The	 timely	 resolution	 of	 inflammation	 is	 a	 fundamental	 requirement	 for	 restoring	 homeostasis	
following	 infection	or	 damage,	with	 its	 failure	 being	 a	 significant	 contributory	 factor	 to	 numerous	
chronic	inflammatory	pathologies.	Macrophages	are	key	players	in	this	process,	given	their	ability	to	
transition	 from	generally	pro-inflammatory	 to	anti-inflammatory	phenotypes	 (7).	Substantial	effort	
has	gone	into	deciphering	the	complex	signals	underpinning	macrophage	plasticity,	with	numerous	
soluble	mediators	having	been	implicated	(11),	but	the	mechanistic	link	between	these	factors	and	
changes	 in	 phenotype	 remains	 poorly	 understood	 especially	 when	 investigated	 in	 specific	 tissue-
restricted	 settings.	 In	 the	 current	 study,	we	 have	 employed	 a	well-characterised	model	 of	muscle	
injury	 and	 recovery	 (13)	 to	 identify	 the	 ability	 of	myeloid	 cell-derived	ANXA1	 to	 promote	 an	 anti-
inflammatory	macrophage	phenotype,	promoting	resolution	and	tissue	repair.	Moreover,	we	show	
the	 actions	 of	 this	 protein	 to	 be	 mediated	 through	 the	 cell	 surface	 receptor	 FPR2/ALX	 and	
downstream	activation	of	the	intracellular	signalling	molecule	AMPK,	mechanistically	linking	external	
and	intracellular	pro-resolving	signals	governing	macrophage	phenotype.		
	
These	data	reinforce	the	identification	of	the	ANXA1-FPR2/ALX	pair	as	a	major	endogenous	driver	of	
inflammatory	 resolution,	 and	 add	 to	 its	 known	 roles	 in	 regulating	 neutrophil	 apoptosis	 (17),	
efferocytosis	(20,	30),	and	the	recruitment	of	monocytes	to	inflammatory	sites	(18).	Notably,	despite	
muscle	 tissue	 itself	 beginning	 to	 express	 ANXA1	 during	 tissue	 repair,	 as	 noted	 previously	 (31),	
experiments	 with	 chimeric	 mice	 confirmed	 that	 in	 our	 experimental	 settings	 the	most	 important	
source	of	the	protein	to	enable	muscle	repair	remains	the	myeloid	cells	themselves.	Moreover,	while	
previous	 studies	 have	 highlighted	 a	 direct	 plasma	 membrane	 action	 for	 extracellular	 ANXA1	 in	
myoblast	 fusion	 in	 vitro	 (32,	 33)	 our	 experiments	 indicate	 that	 Fpr2/3,	 the	 receptor	 target	 for	
ANXA1,	is	not	expressed	by	stromal	and	parenchymal	cells	in	vivo.	This	suggests	that,	at	least	in	the	
context	of	skeletal	muscle	regeneration	post-cardiotoxin	application,	the	action	of	ANXA1	is	mainly	
mediated	 by	 myeloid	 cells,	 which	 in	 turn	 regulate	 myogenic	 cells.	 While	 our	 studies	 do	 not	
absolutely	 identify	 whether	 neutrophils	 or	 macrophages	 are	 the	 primary	 source	 of	 endogenous	
ANXA1	 within	 the	 injured	 tissue,	 neutrophils	 contain	 substantial	 amounts	 of	 this	 mediator	 (34),	
which	we	have	previously	shown	to	be	a	major	monocyte	chemoattractant	(18),	suggesting	that	the	
protein	-	produced	at	an	early	stage	by	and	released	from	infiltrating	neutrophils	(35)		-	may	act	to	
both	 recruit	 monocytes	 and	 promote	 a	 pro-resolving	 phenotype	 in	 the	 resulting	 macrophages.	
Irrespective	of	the	cell	which	is	the	source	of	ANXA1,	the	dependency	upon	the	presence	of	ANXA1-
expressing	 leukocytes	 for	 efficient	macrophage	phenotypic	 conversion	 is	 another	 example	 of	 how	
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“the	 beginning	 programs	 the	 end”	 in	 resolution	 (36),	 emphasising	 the	 finely	 tuned	 nature	 of	 the	
acute	inflammatory	response	and	its	ability	to	encode	its	own	termination.	
	
Besides	highlighting	the	role	of	ANXA1	as	a	regulator	of	inflammatory	resolution	(37),	these	data	add	
further	weight	to	the	 importance	of	 its	receptor	FPR2/ALX	 in	this	process,	 identifying	 it	as	a	major	
determinant	 for	 induction	of	 a	pro-resolving	macrophage	phenotype	 through	AMPK	activation.	Of	
note,	 macrophage	 FPR2/ALX	 expression	 declined	 during	 the	 course	 of	 the	 response	 to	 muscular	
injury;	 congruently,	 FPR2/ALX	 expression	 was	 significantly	 lower	 in	 M2-like	 macrophages	 when	
compared	with	M1-like	phenotype	cells	in	vitro.	This	modulation	of	receptor	expression	may	reflect	
a	mechanism	whereby	once	the	macrophage	is	polarised	towards	a	reparative	phenotype,	the	utility	
of	the	FPR2/ALX	signalling	is	no	longer	necessary.	
	
There	is	considerable	redundancy	in	the	mediators	known	to	induce	the	conversion	of	macrophage	
phenotypes,	 a	 feature	 that	 is	 perhaps	 expected	 given	 the	 importance	 of	 this	 cellular	 process	 to	
promote	 restoration	 of	 homeostasis	 after	 infection	 or	 damage;	 these	 factors	 include	 immune	
complexes,	apoptotic	cells	and	specific	cytokines	(38).	Notably	however,	a	significant	proportion	of	
these	 macrophage-polarising	 mediators	 derive	 from	 the	 adaptive	 arm	 of	 the	 immune	 response,	
particularly	from	TH2	lymphocytes	(11).	Herein,	we	identify	signalling	components	derived	from	the	
innate	 side	 of	 the	 immune	 system	 to	 promote	 resolution.	 Moreover,	 these	 results	 support	 the	
concept	 of	 how	 it	 is	 crucial	 to	 decipher	 mediators	 and	 signal(s)	 operative	 in	 specific	 tissues	 and	
organs	 to	 control	macrophage	polarisation	hence	 to	 regulate	 the	whole	process	of	 resolution	and	
repair.		
	
Our	 data	 associate	 activation	of	 FPR2/ALX	 and	 the	major	 regulator	 of	 cellular	metabolism,	AMPK,	
showing	the	central	 involvement	of	FPR2/ALX-stimulated	AMPK	pathway	in	the	 induction	of	a	pro-
resolving	macrophage	phenotype.	The	precise	mechanism	linking	AMPK	activation	with	a	change	in	
phenotype	is	as	yet	unclear,	but	there	is	increasing	evidence	that	changes	in	the	metabolic	status	of	
immune	cells	can	affect	their	 inflammatory	activity	(39,	40).	Pro-inflammatory	dendritic	cells	and	T	
lymphocytes	 are	 characterised	 by	 high	 levels	 of	 glycolysis,	 akin	 to	 the	 Warburg	 metabolic	 shift	
described	 in	 cancer	 (41),	whereas	 immune	cells	with	an	anti-inflammatory	or	pro-resolving	profile	
tend	to	exhibit	greater	mitochondrial	 respiration	 (13,	42,	43).	The	mechanistic	details	of	how	such	
changes	 in	metabolic	phenotype	relate	to	 immune	function,	and	indeed	whether	these	differences	
reflect	 or	 drive	 immunophenotype,	 are	 not	 fully	 elucidated	 (44),	 but	 it	 is	 notable	 that	 AMPK	 is	 a	
significant	promoter	of	mitochondrial	respiration	and	a	regulator	of	glycolysis	through	modulation	of	
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lactate	dehydrogenase	activity	(45),	driven	by	its	ability	to	respond	to	energy	debt	and	an	increased	
AMP:ATP	ratio	(46).	Activation	of	this	pathway	is	ideally	placed	to	induce	the	metabolic	phenotype	
most	closely	associated	with	anti-inflammatory	macrophage	activation,	but	this	hypothesis	requires	
further	investigation.	
	
AMPK	 is	 involved	 in	different	 cellular	mechanisms	 that	 regulate	 skeletal	muscle	homeostasis	 (47).	
Our	 previous	 findings	 highlighted	 the	 importance	 of	 crosstalk	 between	 AMPK	 and	 the	 mTOR	
signalling	pathway	for	the	control	of	muscle	cell	size	in	the	adaptive	response	of	skeletal	muscle	(48–
51).	Moreover,	we	have	recently	shown	that	AMPKα1,	activated	following	phagocytosis,	is	crucial	for	
macrophage	 skewing	 from	 a	 pro-	 to	 an	 anti-inflammatory	 phenotype	 during	 resolution	 (13),	
demonstrating	 that	 the	CAMKKII/AMPKα1	cascade	within	macrophages	 is	 required	 for	proper	and	
complete	 skeletal	 muscle	 regeneration.	 Anti-inflammatory	 macrophages	 promote	 myogenic	
differentiation	 and	 fusion	 (29,	 52,	 53),	 a	 finding	 of	 importance	 for	 skeletal	 muscle	 regeneration	
where	 a	 sequential	 presence	 of	 pro-	 then	 anti-inflammatory	 cells	 is	 necessary	 for	 an	 efficient	
regeneration	process	(23,	24).	We	could	demonstrate	that	macrophages	conditioned	by	ANXA1,	but	
not	the	soluble	mediator	itself,	promoted	myogenic	fusion.		
	
In	summary,	we	present	a	mechanism	governing	the	conversion	of	pro-inflammatory	macrophages	
to	 a	 pro-resolving	 phenotype,	 linking	 leukocyte-derived	 ANXA1,	 FPR2/ALX	 and	 intracellular	 AMPK	
activation.	 Altogether,	 these	 data	 identify	 the	 ANXA1-FPR2/ALX	 pathway	 as	 a	 pivotal	 regulator	 of	
inflammatory	resolution	with	non-redundant	downstream	actions	on	tissue	repair.	As	such,	ANXA1	
and	FPR2/ALX	represent	suitable	targets	for	therapeutic	exploitation	for	the	innovative	treatment	of	
pathologies	characterised	by	chronic,	non-resolving	inflammation.		
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Figure	Legends	
Figure	1.	Non-redundant	role	of	ANXA1	in	cardiotoxin-induced	muscle	injury	and	repair.	
(A)	 Experimental	 set-up.	 Acute	 injury	 was	 induced	 by	 cardiotoxin	 (CTX)	 injection	 in	 the	 Tibialis	
Anterior	(TA)	of	Wild-Type,	AnxA1-/-	and	Fpr2/3-/-	mice.	Muscles	were	analysed	0,	7	and	28	days	after	
injury.	(B)	TA	mass	normalised	to	mouse	body	weight.	(C)	Hematoxylin-eosin	(HE)	staining	of	muscles	
28	days	after	 injury.	White	bar	=	50	μm.	 (D-E)	Myofibre	cross-sectional	area	 (D),	number	of	nuclei	
per	myofibre	 (E)	 and	 lipid	accumulation	 (F)	 in	muscles	28	days	post-CTX	 injury.	 (G-H)	Macrophage	
subtypes	analysis	2	days	post-CTX	 injury.	Shown	are	the	percentage	of	pro-	and	anti-inflammatory	
macrophages	within	the	F4/80+	population	(G)	and	the	resolution	index	(H).	Results	are	mean	±	SEM	
of	at	least	three	animals.	*p<0.05,	**p<0.01	and	***p<0.001	versus	Wild-Type.	
	
Figure	2.	Infiltrating	myeloid	cell-derived	ANXA1	controls	muscle	repair.		
(A)	Western	blot	analysis	of	ANXA1	protein	in	total	Tibialis	Anterior	muscle.	Muscles	were	analysed	
0,	1,	2,	4,	7	and	14	days	after	injury.	Shown	are	representative	blots	(top	panel)	and	quantification	of	
ANXA1	to	β-actin	(bottom	panel)	and	ratios.	(B)	RT-qPCR	analysis	of	Anxa1	mRNA	level	in	various	cell	
populations	FACS-sorted	 from	Tibialis	Anterior	muscle.	Muscles	were	analysed	0,	1,	2,	4,	7	and	14	
days	after	injury.	(C)	Experimental	set-up	of	Bone	Marrow	Transplantation	(BMT).	CX3CR1-GFP	mice	
were	 irradiated	and	then	transplanted	with	bone	marrow	cells	 isolated	from	Wild-Type	or	AnxA1-/-	
mice.	 Bone	 marrow	 engraftment	 was	 checked	 on	 a	 blood	 sample	 after	 around	 5	 weeks.	 Then	
animals	were	injured	in	their	Tibialis	Anterior	by	cardiotoxin	(CTX)	injection	and	muscles	analysed	0	
or	 28	 days	 later.	 Engraftment	was	 confirmed	 on	 the	 bone	marrow	 of	 each	 animal	 on	 the	 day	 of	
sacrifice.	(D-E)	HE	staining	(D)	and	myofibre	cross-sectional	area	(E)	of	TA	muscles	28	days	post-CTX	
injury.	White	 bar	 =	 50	 μm.	 Results	 are	mean	 ±	 SEM	 of	 at	 least	 two	 (D14	 in	 A)	 or	 three	muscles.	
*p<0.05	versus	Wild-Type.	
	
Figure	3.	Exogenous	hrANXA1	controls	human	and	mouse	macrophage	polarisation	in	vitro.	
Human	PBMC-derived	macrophages	were	incubated	for	24	hours	with	LPS+IFNγ	to	promote	an	M1-
like	 phenotype,	 prior	 to	 addition	 of	 human	 recombinant	 ANXA1	 (hrANXA1,	 10nM)	 for	 further	 6	
hours.	 (A-B)	Median	 Fluorescent	 Intensity	 (MFI)	 units	measured	 by	 flow	 cytometry	 of	MHCII	 pro-
inflammatory	 (A)	 and	 CD206	 anti-inflammatory	 (B)	 markers.	 Shown	 are	 MFI	 quantification	 (left	
panel)	and	representative	FACS	plots	(right	panel).	(C-F)	RT-qPCR	analysis	of	Tnfa	(C)	and	Nos-2	(D)	
pro-inflammatory	 genes,	 and	 Il-10	 (E)	 and	 Tgfb1	 (F)	 anti-inflammatory	 genes.	 (G-H)	 MFI	 units	 as	
measured	 by	 flow	 cytometry	 of	 MHCII	 pro-inflammatory	 (G)	 and	 CD206	 anti-inflammatory	 (H)	
markers	after	treatment	by	hrANXA1	in	the	presence	or	absence	of	the	FPR2/ALX	antagonist	WRW4	
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(10	µM).	Experiments	were	performed	on	PBMC	from	6	(A-F)	or	3	(G-H)	independent	donors.	Each	
colour	represents	an	independent	PBMC	donor.	*p<0.05	versus	Vehicle.	#p<0.05	versus	Control.	
	
Figure	 4.	 The	 ANXA1/FPR2/ALX	 pathway	 activates	 the	 AMPK	 signalling	 cascade	 in	 human	 and	
murine	macrophages.	
(A)	Schematic	representation	of	the	ANXA1/FPR2/ALX	signalling	cascade.	(B-D)	Western	blot	analysis	
of	pCaMK,	pAMPKα1	and	pACC	in	human	PBMC-derived	macrophages	treated	with	hrANXA1.	Shown	
are	 representative	 blots	 (B)	 and	 quantification	 of	 pAMPKα1	 to	 AMPKα1	 (C)	 and	 pACC	 to	 ACC	 (D)	
ratios.	(E)	Representative	western	blot	(top	panel)	and	quantification	(bottom	panel)	of	pAMPKα1	to	
AMPKα1	 ratio	 in	 human	 PBMC-derived	 macrophages	 treated	 by	 hrANXA1	 in	 the	 presence	 or	
absence	 of	 10	µM	WRW4.	 (F)	 Representative	western	 blot	 (top	 panel)	 and	 quantification	 (bottom	
panel)	 of	 pAMPKα1	 to	 AMPKα1	 ratio	 in	 Wild-Type	 or	 Fpr2/3-/-	 murine	 bone	 marrow	 derived	
macrophages	treated	with	hrANXA1.	Results	are	means	±	SEM	of	at	least	two	(D)	or	three	(C,	E	and	
F)	independent	experiments.	*p<0.05,	**p<0.01	versus	Vehicle.	
	
Figure	5.	Null	or	reduced	AMPK	expression	affects	ANXA1-mediated	macrophage	polarisation.	
(A-B)	 Primary	 macrophages	 derived	 from	Wild-Type	 or	 AMPKα1-/-	 mice	 were	 treated	 with	 10nM	
hrANXA1	and	 the	percentage	of	 cells	expressing	 the	pro-inflammatory	markers	 iNOS	and	CCL3	 (A)	
and	 the	 anti-inflammatory	 markers	 TGFB1,	 CD163	 and	 CD206	 (B)	 was	 determined	 by	
immunofluorescence.	(C-E)	Human	PBMC-derived	macrophages	were	transfected	by	a	non-targeting	
or	 three	 different	 AMPKα1-targeting	 siRNAs	 and	 treated	with	 10	 nM	 hrANXA1	 for	 24	 h.	 AMPKα1	
protein	level	was	determined	by	FACS	(C)	and	the	MFI	units	of	the	pro-inflammatory	MHCII	(D)	and	
anti-inflammatory	CD206	(E)	markers	were	measured	by	flow	cytometry.	(F-I)	Conditioned	medium	
produced	by	murine	macrophages	was	transferred	onto	murine	primary	myoblasts	and	their	fusion	
was	 measured	 by	 immunofluorescence.	 (F)	 Experimental	 set-up.	 (G)	 Representative	 images	 of	
desmin	(red)	and	Hoechst	(blue)	labelling	of	myoblast	cultures.	White	bar	=	50	μm.	(H-I)	Fusion	index	
calculated	 after	 desmin	 labelling.	 Shown	 are	 the	means	 +/-	 SEM	of	 the	 independent	 experiments	
relative	to	the	Wild-Type	Control	(H)	and	the	raw	results	of	each	individual	replicate	(I).	Results	are	
mean	±	SEM	of	at	 least	three	 independent	experiments.	*p<0.05	versus	Mock	or	Control.	##p<0.01	
versus	Wild-Type.	
	
Suppl	Fig	1.	Related	to	Figure	1.			
(A)	HE	staining	of	non-injured	Wild-Type	and	AnxA1-/-	Tibialis	Anterior	(TA)	muscles.	White	bar	=	50	
μm.	 (B)	Myofibre	cross-sectional	area	of	non-injured	Wild-Type	and	AnxA1-/-	TA	muscles.	Shown	 is	
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the	mean	+/-	SEM	of	8	muscles.	(C)	Number	of	nuclei	per	myofibre	in	muscles	7	days	post-CTX	injury.	
(D)	 Representative	 images	 of	 Sudan	 black	 staining	 of	 TA	 muscles	 from	 Wild-Type,	 AnxA1-/-	 and	
Fpr2/3-/-	mice	 28	 days	 post-cardiotoxin	 injury.	 (E)	 Representative	 FACS	 plots	 of	 F4/80	 and	 Ly6C/G	
markers	 in	 TA	 of	 Wild-Type,	 AnxA1-/-	 and	 Fpr2/3-/-	 mice	 2	 days	 post-cardiotoxin	 injury.	 (F-G)	
Macrophage	subtypes	analysis	 in	Wild-Type	and	Fpr1-/-	muscles	2	days	post-CTX	 injury.	Shown	are	
the	percentage	of	pro-	and	anti-inflammatory	macrophages	within	the	F4/80+	population	(F)	and	the	
resolution	index	(G).	Results	are	mean	±	SEM	of	at	least	three	animals.	*p<0.05	versus	Wild-Type.	
	
Suppl	Fig	2.	Related	to	Figure	2.	Gating	strategy	to	 isolate	cell	populations	 from	Tibialis	anterior	
muscle.	
TA	muscles	were	digested	with	Collagenase	B/Dispase	and	cells	were	separated	by	magnetic	beads	
based	on	their	CD45	expression	level.	(A)	CD45pos	cells	were	blocked	with	anti-FcgRII/III	and	labelled	
with	 CD45,	 CD64	 and	 Ly6C	 antibodies	 to	 isolate	 Neutrophils	 (Neut)	 and	 Ly6Cpos	 and	 Ly6Cneg	
macrophages	(Mac).	Shown	are	representative	plots	for	day	4	post-CTX	 injury	together	with	purity	
check	 for	 recovered	populations	 (coloured	boxes).	Numbers	 represent	 sorting	purity	 calculated	as	
percentage	of	live	cells.	(B)	CD45neg	cells	were	labelled	with	CD45,	CD31,	Sca-1,	α7-integrin	and	CD34	
antibodies	 to	 isolate	 endothelial	 cells	 (EC),	 FAPs	 (FAP)	 and	 satellite	 cells	 (SAT).	 Shown	 are	
representative	 plots	 at	 day	 4	 (A)	 and	 day	 1	 (B)	 post-CTX	 injury,	 together	 with	 purity	 check	 for	
recovered	populations	(coloured	boxes).	Numbers	represent	sorting	purity	calculated	as	percentage	
of	live	cells.	
	
Suppl	 Fig	 3.	 Related	 to	 Figure	 2.	 Immune	 cell	 recruitment	 and	 pattern	 of	 AnxA1	 expression	 in	
cardiotoxin-induced	muscle	injury	and	repair.	
(A)	Anxa1	mRNA	level	measured	by	RT-qPCR	on	sorted	cell	populations	from	Tibialis	Anterior	muscle	
after	 cardiotoxin	 injury.	 (B-D)	 Immunofluorescence	 analysis	 of	 ANXA1	 protein	 in	 Tibialis	 Anterior	
muscle	 after	 cardiotoxin	 injury.	 Images	 show	 co-localisation	 of	 ANXA1	 protein	with	 Ly6G+	 (B)	 and	
F4/80+	(C)	cells.	White	bar	=	50	μm.	(D)	Quantification	of	F4/80+	ANXA1+	cells	in	Tibialis	Anterior	(TA)	
muscle	after	cardiotoxin	(CTX)	injury.		
	
Suppl	 Fig	 4.	Related	 to	 Figure	2.	 Immune	 cell	 recruitment	 and	 Fpr2/3	expression	 in	 cardiotoxin-
induced	muscle	injury	and	repair.	
(A)	Fpr2/3	mRNA	level	measured	by	RT-qPCR	on	sorted	cell	populations	from	Tibialis	Anterior	muscle	
after	cardiotoxin	 injury.	 (B-C)	Quantification	of	F4/80+	ANXA1+	cells	 in	Tibialis	Anterior	 (TA)	muscle	
after	cardiotoxin	(CTX)	 injury.	Representative	 immunofluorescence	analysis	of	Fpr2/3	protein	 in	TA	
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muscle	 after	 cardiotoxin	 (CTX)	 injury	 (B)	 and	 quantification	 of	 the	 percentage	 of	 F4/80+	 cells	
expressing	Fpr2/3	(C).	White	bar	=	50	μm.		Results	are	means	±	SEM	of	three	animals.	*p<0.05	and	
***p<0.001	versus	Day	0.		
		
Suppl	Fig	5.	Related	to	Figure	2.	BMT	controls	
(A)	Body	weight	follow-up,	represented	as	percentage	of	Day	0,	of	mice	after	 irradiation	and	bone	
marrow	transplantation.	Results	are	means	±	SEM	of	at	least	six	animals.	*p<0.05	versus	Day	0.	(B-C)	
Representative	FACS	plots	(B)	and	quantification	(C)	of	the	GFP+	monocytes	in	the	bone	marrow	of	
the	sacrificed	animals.	(D-E)	Representative	FACS	plots	(D)	and	quantification	(E)	of	the	percentage	
of	macrophages	with	 host	 or	 donor	 origin	 based	 on	 their	 GFP	 expression.	 Shown	 are	 TA	muscles	
between	day	2	and	day	8	post-CTX	injury.	
	
Suppl	 Fig	 6.	 Related	 to	 Figure	 3.	 FPR2/ALX	 expression	 varies	 following	 human	 macrophage	
polarisation.	
Human	 primary	 macrophages	 were	 polarised	 into	 M1	 or	 M2	 macrophages	 with	 IFNg	 and	 IL-4,	
respectively	(A-C)	Flow	cytometry	analysis	of	FPR2/ALX	expression.	Shown	are	representative	FACS	
plots	(A),	percentage	of	cells	expressing	FPR2/ALX	(B)	and	FPR2/ALX	MFI	(C).	(D)	RT-qPCR	analysis	of	
FPR2/ALX	mRNA	 level.	Results	 are	means	+/-	 SEM	of	 at	 least	 four	 independent	experiments.	 *p	<	
0.05	versus	M0	(non-activated).	
	
Suppl	Fig	7.	Related	to	Figure	5.	
(A)	 Human	 PBMC-derived	 macrophages	 were	 transfected	 by	 a	 non-targeting	 or	 three	 different	
AMPKα1-targeting	 siRNAs	 and	 treated	with	 10	 nM	 hrANXA1	 for	 24	 h.	 AMPKα1	 protein	 level	 was	
determined	by	western	blot.	(B)	Primary	myoblasts	were	differentiated	for	3	days	in	presence	of	10	
nM	hrANXA1	or	conditioned	medium	produced	by	murine	macrophages	treated	by	10	nM	hrANXA1.	
Each	dot	corresponds	to	an	independent	experiment.	
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Methods	
Animals		
All	procedures	were	performed	under	the	UK	Animals	(Scientific	Procedures)	Act,	1986	in	the	UK	or	
in	 compliance	 with	 European	 legislation	 in	 France.	 Animal	 facilities	 are	 fully	 licensed	 by	 relevant	
national	 authorities	 and	protocols	 have	 been	 validated	 by	 local	 ethical	 committees.	Male	 C57Bl/6	
mice,	male	alx/fpr2/3GFP/GFP	mice	 (referred	 to	 as	 Fpr2/3-/-)	 bearing	 a	 knocked-in	 green	 fluorescent	
protein	 (27)	 and	male	anxA1-/-	mice	 (54),	 aged	10	weeks	were	used	 for	 in	 vivo	experiments.	 Both	
transgenic	strains	were	fully	backcrossed	onto	a	C57Bl/6	genetic	background.		
	
Production	of	Recombinant	Human	Annexin	A1	
Human	recombinant	annexin	A1	 (hrANXA1)	was	produced	by	a	prokaryotic	expression	system	and	
purified	essentially	as	described	previously	 (55).	Briefly,	cDNA	for	human	ANXA1	was	 inserted	 into	
the	 expression	 vector	 pQE30Xa	 (Qiagen)	 and	 transfected	 into	 E.coli	 (#SG13009	 pREP4,	 Novagen)	
which	 were	 then	 grown	 in	 Luria-Bertani	 broth	 medium	 supplemented	 with	 ampicillin	 (50	 μg/ml,	
Roche),	kanamycin	(30	μg/ml,	Thermofisher)	and	0.5%	glycerol.	Protein	overexpression	was	initiated	
by	addition	of	5mM	isopropyl	β-D-1-thiogalactopyranoside	(Eurogentec)	and	proteins	were	purified	
by	 IMAC.	 Purity	 and	 homogeneity	 were	 assessed	 by	 SDS-PAGE,	 western	 blotting	 and	 MALDI-
TOF/TOF	 analysis.	 Endotoxin	 was	 determined	 with	 the	 Endosafe-PTS	 (FDA-licensed	 LAL	 cartridge	
from	 Charles-River)	 according	 to	 the	 manufacturer’s	 protocol.	 HrANXA1	 contained	 <	 0.2	 unit	
endotoxin	per	mg	hrANXA1	protein.	
	
Skeletal	Muscle	Injury	
Skeletal	muscle	injury	was	caused	by	intramuscular	 injection	of	cardiotoxin	(Latoxan)	 in	the	Tibialis	
Anterior	 (TA)	muscle	of	male	animals,	as	described	previously	 (13).	TA	muscles	were	 injected	with	
cardiotoxin	 (50	 µl	 per	 TA,	 12	 µM);	 1,	 2,	 7,	 14	 or	 28	 days	 post-lesioning	 animals	 were	 killed	 by	
exposure	to	CO2.	TA	were	isolated	and	snap-frozen	in	liquid	nitrogen-cooled	isopentane	for	storage	
and	 later	 analysis.	 Only	 muscles	 harbouring	 more	 than	 90	 %	 of	 myofibres	 with	 centrally	 located	
nuclei	were	considered	for	analysis.	
	
Murine	Bone	Marrow-Derived	Macrophages		
Bone	 marrow-derived	 macrophages	 (BMDMs)	 were	 prepared	 from	 adult	 male	 wild-type	
sv129/C57Bl6	 and	 Prkaa1-/-	 mice	 (referred	 to	 as	 AMPKα1-/-	 (28))	 .	 Mice	 were	 killed	 by	 cervical	
dislocation	 under	 isofluorane	 anaesthesia,	 and	marrow	was	 flushed	 from	 tibiae	 and	 femurs.	 Cells	
were	 plated,	 washed	 and	 grown	 for	 6-7	 days	 in	 DMEM	 High	 Glucose	 High	 Pyruvate,	 20%	 heat	
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inactivated	fetal	calf	serum	(ThermoFisher),	30%	L929-cell	conditioned	medium,	1%	Amphotericin	B	
(2.5	 µg/ml,	 ThermoFisher)	 and	 100	 μg/ml	 streptomycin	 (ThermoFisher).	 For	 phenotypic	
characterisation,	BMDMs	were	treated	for	6	hours	 in	presence	or	absence	of	10	nM	hrANXA1	and	
fixed	for	10	minutes	in	4%	formaldehyde,	permeabilized	for	10	minutes	in	PBS	with	0.5	%	Triton	X-
100	and	blocked	for	1	hour	in	PBS	with	4	%	BSA.	They	were	then	labeled	overnight	at	4°C	with	anti-
NOS2	 (#ab15323,	 Abcam),	 anti-CCL3	 (#ab32609,	 Abcam),	 anti-TGFβ1	 (#ab64715,	 Abcam),	 anti-
CD163	(#sc-20066,	Santa-Cruz)	and	anti-CD206	(#sc-58987,	Santa-Cruz),	followed	by	incubation	for	1	
hour	at	37°C	with	FITC-	or	Cy3-conjugated	secondary	antibodies	(Jackson	Immunoresearch	Inc).	Cells	
were	 stained	 with	 Hoechst	 (Sigma)	 and	 mounted	 in	 Fluoromount	 (Interchim)	 and	 pictures	 were	
taken	 on	 an	 Axio	 Imager.Z1	 (Zeiss)	 at	 20X	 of	 magnification	 connected	 to	 a	 CoolSNAP	 MYO	 CCD	
Camera	(Photometrics).	
	
In	vitro	model	of	adult	myogenesis	
Macrophages	were	 obtained	 from	bone	marrow	 (BM)	 precursor	 cells	 extracted	 from	 four	 distinct	
mice	that	were	cultured	in	DMEM	containing	20%	FBS	and	30%	conditioned	medium	of	L929	cell	line	
(enriched	in	CSF-1)	for	7	days.	Macrophages	were	activated	with	human	recombinant	annexin	A1	for	
3	days	(10	nM)	in	DMEM	containing	10%	FBS.	After	the	washing	steps,	serum-free	DMEM	was	added	
for	24	hr	to	obtain	macrophage-conditioned	medium.	Murine	myogenic	precursor	cells	(MPCs)	were	
obtained	 from	 TA	 muscle	 isolated	 from	 four	 mice	 and	 cultured	 using	 standard	 conditions	 in	
DMEM/F12	medium	(Gibco	Life	Technologies)	containing	20%	heat	inactivated	Foetal	Bovine	Serum	
(FBS)	and	2%	G/Ultroser	(Pall	Inc).	MPCs	were	seeded	at	30,000	cell/cm2	on	Matrigel	(diluted	1:10)	
and	incubated	for	3	days	with	conditioned	medium	containing	2%	heat	inactivated	horse	serum.	In	
the	 case	of	direct	 treatment	of	MPCs,	 cells	were	directly	 incubated	with	10	nM	of	hrANXA1	 for	3	
days	in	presence	of	2%	heat	inactivated	horse	serum.	Cells	were	then	incubated	with	an	anti-desmin	
antibody	 (#ab32362,	 Abcam),	 followed	 by	 a	 Cy3-conjugated	 secondary	 antibody	 (Jackson	
Immunoresearch	Inc)	(13,	29).	Cells	were	stained	with	Hoechst	(Sigma)	and	mounted	in	Fluoromount	
(Interchim)	and	pictures	were	taken	on	Axio	Observer.Z1	(Zeiss)	at	20X	of	magnification	connected	
to	a	CoolSNAP	HQ2	CCD	Camera	(Photometrics	
	
Bone	Marrow	Transplantation	
Bone	Marrow	Transplantation	was	performed	as	previously	described	(13,	56).	Total	bone	marrow	
cells	were	isolated	by	flushing	the	tibiae	and	femurs	of	8-	to	20-week-old	donor	mice	(wild-type	or	
AnxA1-/-	males)	with	RPMI-1640	/	10%	FBS.	They	were	transplanted	into	8-	to	12-week-old	recipient	
CX3CR1-GFP+/-	males	(monocytes/macrophages	expressing	GFP)	previously	lethally	irradiated	for	10	
	 20	
min	with	a	dose	of	0.85	Gy/min	 in	an	X-RAD	320	 (Precision	X-Ray).	 Total	bone	marrow	cells	were	
injected	(107	cells	diluted	in	100	μL	of	RPMI-1640	/	50	%	mouse	serum)	into	the	retro-orbital	vein	of	
recipient	 mice.	 After	 transplantation,	 mice	 were	 fed	 with	 ciprofloxacin	 (10	 mg/kg/day)	 in	 the	
drinking	 water	 for	 3-weeks.	 Engraftment	 efficiency	 was	 determined	 on	 peripheral	 blood	 5	 weeks	
after	the	transplantation	and	on	bone	marrow	when	mice	were	sacrificed	by	FACS	analysis.	Briefly,	
red	 cells	 were	 lysed	 with	 ACK	 buffer	 and	 leukocytes	 were	 incubated	 with	 FcR	 Blocking	 Reagent	
(Miltenyi	Biotec)	 for	 20	min	 at	 4°C.	 Finally,	 cells	were	 labeled	with	 an	APC-conjugated	anti-CD115	
antibody	for	30	min	at	4°C	and	analysed	on	a	BD	FACS	Canto	II	(BD	Biosciences).	DAPI	was	used	as	
viability	marker.	Engraftment	was	determined	as	the	percentage	of	monocytes	not	expressing	GFP.	
	
Human	Peripheral	Blood-Derived	Macrophages	
Human	 cells	 were	 prepared	 according	 to	 an	 approved	 protocol	 (East	 London	 &	 the	 City	 Local	
Research	 Ethics	 Committee;	 no.	 06/Q605/40;	 P/00/029).	 Peripheral	 blood	 was	 collected	 from	 6	
different	 healthy	 volunteers	 by	 intravenous	 withdrawal	 in	 3.2%	 sodium	 citrate	 solution	 (1:10).	
Peripheral	 blood	mononuclear	 cells	were	 isolated	by	density	 centrifugation	on	 a	Histopaque-1077	
gradient	(Sigma)	according	to	the	manufacturer’s	 instructions,	and	were	plated	 in	RPMI	1640	for	1	
hour.	Cells	were	washed	 three	 times	with	 ice-cold	PBS	without	Ca2+/Mg2+	 to	 remove	 lymphocytes,	
and	adherent	cells	were	incubated	in	RPMI	1640	containing	20%	heat	inactivated	fetal	calf	serum	for	
14	days.	
	
Histological	and	Immunohistochemical	Analysis	
For	histological	analysis,	muscles	were	harvested,	snap	 frozen	 in	 liquid	nitrogen-chilled	 isopentane	
and	kept	at	-80°C	until	use.	Cryosections	(10µm)	were	prepared	for	hematoxylin-eosin	(HE)	or	Sudan	
Black	staining.	Stained	sections	were	scanned	using	an	Axio	Scan.Z1	(Zeiss)	with	a	20x	objective	an	a	
3	CCD	HV-F	2025	CL	 camera	 (Hitachi)	and	Sudan	Black	 labelled	areas	were	quantified	with	 ImageJ	
software.	 Briefly,	 images	were	 converted	 into	 8-bit	 binary	 image	 using	 “Yen”	 threshold	 filter	 and	
black	pixels	were	numerated	and	expressed	as	a	percentage	of	the	total	pixels	in	the	muscle	section.		
Fluorescence	 immunohistochemical	 analysis	 was	 performed	 according	 to	 standard	 procedures.	
Briefly,	transverse	muscle	cryosections	(10	µm)	were	post-fixed	by	incubation	for	15	minutes	in	4%	
formaldehyde,	blocked	and	 immunostained	using	primary	antibodies	directed	against	Ly6G	(1:100;	
#127602,	Biolegend),	F4/80	(1:200,	#123102,	Biolegend)	ANXA1	(1:1,000;	#71-3400,	ThermoFisher)	
or	 Fpr2/3	 (1:100,	 #sc-18191-R,	 SantaCruz).	 Secondary	 antibodies	 were	 Alexa	 Fluor	 488-	 or	 594-
conjugated	 goat	 anti-rabbit	 or	 anti-rat	 IgG	 (1:300;	 Invitrogen).	 Sections	were	 counterstained	with	
DAPI,	 mounted	 and	 examined	 using	 a	 TCS	 SP5	 confocal	 laser	 scanning	 microscope	 (Leica	
	 21	
Microsystems)	fitted	with	405	nm,	488	nm	and	594	nm	lasers,	and	attached	to	a	Leica	DMI6000CS	
inverted	 microscope	 fitted	 with	 a	 40×	 objective	 lens	 (NA	 0.75	 mm;	 working	 distance,	 0.66	 mm).	
Images	were	captured	with	Leica	LAS	AF	2.6.1	software	and	analysed	using	ImageJ	1.51w	software	
(National	Institutes	of	Health).	
	
In	vivo	Macrophage	Phenotype	Analysis	
Macrophage	phenotype	was	analyzed	as	previously	described	(13).	Briefly,	CD45+	cells	were	isolated	
from	 regenerating	 muscle	 TA	 using	 magnetic	 beads	 conjugated	 to	 anti-CD45	 antibody	 (Milteny	
Biotec)	and	then	incubated	with	Fc-block	(Milteny	Biotec)	for	30	min	at	4°C.	Finally,	CD45+	cells	were	
stained	with	antibody	against	Ly-6C/G	(#17-5931-82,	eBioscience)	and	against	F4/80	(#12-4801-82,	
eBioscience).	 Percentages	 of	 Ly-6C/GhiF4/80low	 and	 Ly-6C/GnegF4/80hi	 cells	 were	 calculated	 among	
total	 F4/80pos	 cells	 following	 analysis	 by	 flow	 cytometry	 with	 a	 FACSCalibur	 instrument	 (Becton	
Dickinson,	UK)	and	FlowJo	v.9.2	analysis	software	as	described	below.	
	
AMPKα1	siRNA	
Primary	 human	 PBMC-derived	 macrophages	 were	 transfected	 with	 one	 of	 three	 different	
commercial	 siRNA	 sequences	 designed	 to	 target	 AMPKα1	 or	 an	 Allstars	 negative	 control	 siRNA	
sequence	 using	 Hiperfect	 transfection	 reagent	 according	 to	 the	manufacturer’s	 instructions	 (final	
concentration	2	nM;	all	Qiagen	GmbH,	Hilden,	Germany),	alongside	mock	transfected	cells.	After	48	
hours,	 cells	 were	 analysed	 for	 phenotypic	 conversion	 following	 hrANXA1	 treatment	 (6	 hours,	 10	
nM).	A	proportion	of	cells	were	analysed	for	AMPKα1	expression	by	western	blot	as	described	below	
or	by	flow	cytometry.	Briefly,	48h	after	siRNA	transfection	cells	were	detached,	fixed	by	incubation	
in	4%	formaldehyde	in	PBS	at	4°C	for	10	min,	and	permeabilised	by	resuspension	with	vortexing	in	
ice-cold	 methanol.	 Surface	 FcγR	 were	 blocked	 by	 incubation	 for	 20	 min	 at	 4°C	 with	 IgG	 block	
(ThermoFisher	 Scientific,	 UK)	 then	 incubated	 for	 30	min	 at	 4°C	 with	 a	 rabbit	 polyclonal	 antibody	
raised	against	the	human	AMPKα1	subunit	(1:1,000,	#2795,	Cell	Signalling	Technology),	followed	by	
an	 AF488-conjugated	 goat	 anti-rabbit	 polyclonal	 secondary	 antibody	 (1:500,	 #A-11008,	
ThermoFisher	 Scientific,	 UK)	 staining.	 Cells	were	 analysed	 on	 a	 FACS	 Canto	 II	 flow	 cytometer	 (BD	
Biosciences,	 UK)	 and	 using	 FlowJo	 8.8.2	 analysis	 software.	 A	 total	 of	 10,000	 singlet	 events	 were	
analysed	for	each	sample.		
	
Human	Macrophage	Flow	Cytometry	Analysis	
Primary	human	PBMC-derived	macrophages	were	labelled	with	FITC-conjugated	mouse	monoclonal	
anti-MHCII	 (#11-9956-42,	 Thermofisher)	 and	 APC-conjugated	mouse	monoclonal	 anti-CD206	 (#17-
	 22	
2069-42,	Thermofisher)	or	isotype	controls	(all	Thermofisher)	according	to	manufacturer’s	protocols.	
In	 all	 cases,	 20,000	 events	were	 acquired	 using	 a	 FACSCalibur	 flow	 cytometer	 (Becton	Dickinson),	
and	analysed	using	FlowJo	analysis	software	(Version	9.2,	Treestar	Inc).	In	some	cases,	macrophages	
were	analysed	for	surface	expression	of	FPR2/ALX;	surface	FcγR	were	blocked	by	incubation	for	20	
minutes	at	4°C	with	IgG	block	(ThermoFisher	Scientific,	UK),	followed	by	incubation	for	30	minutes	at	
4°C	with	mouse	monoclonal	 anti-FPR2/ALX	 (1µg/106	 cells;	 GM1D6,	 Aldevron,	 Freiburg,	 Germany)	
then	incubation	for	30	minutes	at	4°C	with	secondary	antibody	(AF488-conjugated	goat	anti-mouse	
1:300;	ThermoFisher	Scientific,	UK).		
	
Western	Blot	Analysis	
Mouse	muscle	tissue	and	human	macrophage	samples	were	homogenised	in	RIPA	buffer	containing	
phosphatase	 and	 protease	 inhibitor	 cocktail	 (ThermoFisher	 Scientific,	 UK).	 Samples	 boiled	 in	 6×	
Laemmli	 buffer	 were	 subjected	 to	 standard	 SDS-PAGE	 (10%)	 and	 electrophoretically	 blotted	 onto	
Immobilon-P	 polyvinylidene	 difluoride	 membranes	 (Millipore,	 Watford,	 UK).	 Membranes	 were	
incubated	 with	 antibodies	 raised	 against	 human	 phospho-Ca2+/calmodulin-dependent	 kinase	
(#12716,	Cell	Signalling	Technology),	phospho-AMPKα	(#2531,	Cell	Signalling	Technology),	AMPKα1	
(#2795,	 Cell	 Signalling	 Technology),	 phospho-acetyl-CoA	 carboxylase	 (#3661,	 Cell	 Signalling	
Technology),	acetyl-CoA	carboxylase	(#3662,	Cell	Signalling	Technology,	all	1:1000),	ANXA1	(1:1000,	
#71-3400,	 ThermoFisher	 Scientific,	 UK)	 or	 β-actin	 (1:10,000;	 #A5316,	 Sigma)	 in	 Tris-buffer	 saline	
solution	containing	0.1	%	Tween-20	and	5	%	 (w/v)	non-fat	dry	milk	overnight	at	4	 °C.	Membranes	
were	washed	 for	 30	minutes	with	 Tris-buffer	 saline	 solution	 containing	 0.1	%	 Tween-20,	with	 the	
solution	 being	 changed	 at	 10	 minute	 intervals;	 membranes	 were	 then	 incubated	 with	 secondary	
antibody	(horseradish	peroxidase–conjugated	goat	anti-mouse	1:5000;	ThermoFisher),	for	2	hours	at	
room	temperature.	Proteins	were	then	detected	using	the	enhanced	chemiluminescence	detection	
kit	 and	 visualized	 on	 Hyperfilm	 (Amersham	 Biosciences).	 Films	 were	 digitised	 and	 analysed	 using	
ImageJ	1.51w	software	(National	Institutes	of	Health).	
	
Quantitative	RT-PCR	
Total	RNA	was	prepared	from	primary	human	PBMC-derived	macrophages	using	TRIzol	reagent	(Life	
Technologies	 Ltd),	 and	 then	 reverse	 transcribed	 with	 superscript	 III	 reverse	 transcriptase	 (Life	
Technologies	Ltd)	according	to	the	manufacturer’s	protocols.	Resultant	cDNA	was	then	analysed	by	
real-time	PCR	in	duplicate,	using	the	Quantitect	primer	system	(Primer	sets:	FPR2/ALX	QT00204295,	
IL-10	QT00041685,	NOS-2	QT00068740,	TNF-α	QT00029162	and	TGFβ1	QT00000728;	all	Qiagen	Ltd.)	
and	Power	SYBR	Green	PCR	Master	Mix	(Applied	Biosystems).	Reactions	were	performed	in	384	well-
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format	using	the	ABI	Prism	7900HT	Sequence	Detection	System.	The	PCR	conditions	consisted	of	95	
°C	15	min,	[95	°C	15	s − 55	°C	30	s − 72	°C	30	s] × 40,	with	a	dissociation	step	[95	°C	15	s/60	°C	15	s/95	
°C	15	s]	 included	after	the	PCR	reaction	to	confirm	the	absence	of	non-specific	products.	Data	was	
acquired	and	analyzed	with	SDS	2.3	(Applied	Biosystems);	fold	change	was	calculated	as	2−ΔΔCt.	
	
For	 Anxa1	 and	 Fpr2/3	 RT-qPCR	 analysis,	 cell	 populations	 were	 FACS-sorted	 from	 mouse	 Tibialis	
Anterior	muscles	as	previously	described	(57)	using	a	FACS	Aria	II	cell	sorter	(BD	Biosciences).	Total	
RNA	 was	 isolated	 using	 NucleoSpin	 RNA	 Plus	 XS	 kit	 (Macherey-Nagel)	 and	 retro-transcribed	 into	
cDNA	 using	 Superscript	 II	 Reverse	 Transcriptase.	 qPCR	 was	 performed	 in	 triplicates	 on	 a	 CFX	
ConnectTM	Real-Time	PCR	Detection	 System	 (Bio-Rad)	using	 LightCycler®	480	 SYBR	Green	 I	Master	
(Roche	 Diagnostics).	 Calculation	 of	 relative	 expression	 was	 determined	 by	 the	 Bio-Rad	 CFX	
ManagerTM	software	and	fold	change	was	normalised	as	Normalised	Relative	Quantity	(or	ΔΔCq)	for	
each	series,	as 𝑁𝑅𝑄 = !∆!"#!!"!#$!∆!"#!!"!#$	where	T	 is	 the	 target	sample,	Cal	 is	 the	calibrator	value	 (i.e.	 the	
mean	of	 all	 sample	 Cqs	 of	 the	 series)	 and	R	 is	 the	 housekeeping	 gene	Cyclophilin	A.	 Sequence	 of	
primers	 used	 were	 as	 follows:	 5’-GCACTCCAGCTTTCTTTGCC-3’	 (Anxa1	 fwd),	 5’-
AATTTCCGAACGGGAGACCA-3’	 (Anxa1	 rev),	 5’-ACACCACAGGAACCGAAGAG-3'	 (Fpr2/3	 fwd),	 5’-
TGGAGACAACCACCATTGAGA-3'	(Fpr2/3	rev),	5’-	GTGACTTTACACGCCATAATG	-3’	(Cyclophilin	A	fwd)	
and	5’-	ACAAGATGCCAGGACCTGTAT	-3’	(Cyclophilin	A	rev).	
	
Statistical	Analysis	
All	 quantified	 in	 vitro	 data	 are	derived	 from	at	 least	 three	 independent	 donors,	with	 experiments	
performed	 in	 triplicate,	 and	 are	 expressed	 as	 mean	 ±	 SEM.	 Murine	 in	 vivo	 experiments	 were	
performed	with	a	group	size	of	n=6,	sufficient	to	identify	a	20%	effect	size	with	a	power	of	0.8,	and	
are	 expressed	 as	 mean	 ±	 SEM.	 All	 mice	 were	 randomly	 allocated	 to	 groups,	 and	 analysis	 was	
performed	blinded	 to	 experimental	 condition.	Data	were	 analysed	by	 one-	 or	 two-way	ANOVA	as	
appropriate,	with	post	hoc	 comparison	using	Tukey’s	HSD	test.	For	murine	 in	vitro	experiments,	at	
least	3	independent	experiments	were	performed	and	statistical	significance	was	determined	using	
Student’s	t	test.	In	all	cases,	a	P<0.05	was	taken	as	indicating	statistical	significance.	
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